Country websites:


The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

Not all products are cleared or available for sale in all countries.

By clicking on the button "Accepted and Confirmed" you assure that you have taken note of this information and that you are a healthcare professional.


A treatment option for removing IgE

IgEnio® IgE adsorber

IgEnio® is a flexible therapy option for patients suffering from severe stages of allergic symptoms. It selectively removes type IgE antibodies from the plasma in a single treatment. IgEnio® presents a valuable therapy option for patients with high IgE levels, where conventional treatments prove ineffective.

IgEnio® achieved an average IgE-reduction of 88% per cycle (including three treatments)2

Mean IgE levels during cycle one of the ESPIRA study2

IgEnio® uses a specific ligand with high affinity for IgE

After separation from other blood components, the plasma is passed through the IgEnio® adsorber column, where IgE binds to ScFv12. ScFv12 is an anti-IgE antibody-derived single-chain fragment with a high affinity for human IgE.

ESPIRA study results
Above: chart adapted from ESPIRA study Adverse events were successfully controlled by standard medication in all cases and treatment could be reliably performed2.

Clinical setup

Treatment setup for IgEnio® simply requires a centrifuge (e.g., Fresenius Kabi COM.TEC®) for plasma generation.

Clinical setup for IgEnio
Clinical setup for IgEnio® Adapted from Lupinek C et al2

Related therapies

1. IgEnio® - Instructions for use
2. Lupinek C et al, Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy (ESPIRA Study), EBioMedicine, Mar. 2017; 17: 119–33.
3. IgEnio® Preparation Kit - Instructions for use